Complete financial analysis of Milestone Scientific Inc. (MLSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Milestone Scientific Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Mobi724 Global Solutions Inc. (MOBIF) Income Statement Analysis – Financial Results
- Stargaze Entertainment Group Inc. (STGZ) Income Statement Analysis – Financial Results
- Epsilon Energy Ltd. (EPSN) Income Statement Analysis – Financial Results
- Latteys Industries Limited (LATTEYS.NS) Income Statement Analysis – Financial Results
- Atlas Copco AB (0XXV.IL) Income Statement Analysis – Financial Results
Milestone Scientific Inc. (MLSS)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.milestonescientific.com
About Milestone Scientific Inc.
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.83M | 8.81M | 10.30M | 5.44M | 8.37M | 9.62M | 11.28M | 10.48M | 9.49M | 10.33M | 10.01M | 8.65M | 8.38M | 9.75M | 8.55M | 6.62M | 6.39M | 5.84M | 6.43M | 4.75M | 3.97M | 4.07M | 4.09M | 5.67M | 2.86M | 8.80M | 2.90M | 300.00K |
| Cost of Revenue | 3.03M | 3.91M | 3.99M | 1.82M | 2.66M | 5.19M | 4.31M | 4.18M | 3.05M | 3.63M | 3.20M | 3.06M | 3.02M | 3.53M | 3.46M | 2.68M | 2.90M | 3.04M | 2.52M | 2.42M | 2.00M | 1.98M | 1.97M | 2.91M | 839.46K | 9.60M | 1.60M | 0.00 |
| Gross Profit | 6.79M | 4.90M | 6.31M | 3.62M | 5.72M | 4.43M | 6.97M | 6.31M | 6.44M | 6.70M | 6.81M | 5.59M | 5.36M | 6.22M | 5.09M | 3.94M | 3.49M | 2.81M | 3.91M | 2.34M | 1.97M | 2.09M | 2.12M | 2.77M | 2.02M | -800.00K | 1.30M | 300.00K |
| Gross Profit Ratio | 69.12% | 55.65% | 61.25% | 66.60% | 68.28% | 46.05% | 61.77% | 60.16% | 67.88% | 64.86% | 68.05% | 64.66% | 63.99% | 63.78% | 59.55% | 59.52% | 54.65% | 48.06% | 60.81% | 49.15% | 49.56% | 51.38% | 51.80% | 48.75% | 70.60% | -9.09% | 44.83% | 100.00% |
| Research & Development | 701.38K | 1.15M | 878.21K | 307.85K | 189.92K | 245.64K | 272.75K | 1.27M | 100.86K | 88.24K | 191.35K | 181.98K | 140.05K | 270.49K | 241.32K | 168.52K | 397.35K | 1.01M | 286.26K | 187.99K | 131.02K | 147.71K | 49.94K | 386.25K | 455.33K | 400.00K | 1.00M | 200.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.65M | 11.93M | 11.55M | 9.40M | 7.40M | 5.53M | 5.93M | 6.45M | 6.65M | 6.95M | 5.50M | 6.34M | 5.33M | 6.79M | 5.16M | 3.57M | 3.59M | 5.27M | 8.50M | 7.01M | 9.30M | 7.70M | 2.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.14M | 12.51M | 12.74M | 10.77M | 9.53M | 10.65M | 11.93M | 11.55M | 9.40M | 7.40M | 5.53M | 5.93M | 6.45M | 6.65M | 6.95M | 5.50M | 6.34M | 5.33M | 6.79M | 5.16M | 3.57M | 3.59M | 5.27M | 8.50M | 7.01M | 9.30M | 7.70M | 2.20M |
| Other Expenses | 61.91K | 63.76K | 73.84K | -24.79K | -10.41K | -7.23K | -4.93K | -5.09K | -5.35K | 0.00 | 17.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 26.07K | 0.00 | 718.62K | 732.86K | 500.00K | 300.00K | 200.00K |
| Operating Expenses | 13.90M | 13.73M | 13.69M | 11.07M | 9.72M | 10.89M | 12.20M | 12.82M | 9.50M | 7.49M | 5.73M | 6.11M | 6.59M | 6.92M | 7.19M | 5.67M | 6.73M | 6.33M | 7.08M | 5.34M | 3.70M | 3.76M | 5.32M | 9.60M | 8.20M | 10.20M | 9.00M | 2.60M |
| Cost & Expenses | 16.93M | 17.63M | 17.68M | 12.89M | 12.37M | 16.08M | 16.52M | 17.00M | 12.55M | 11.12M | 8.92M | 9.17M | 9.60M | 10.45M | 10.65M | 8.35M | 9.63M | 9.37M | 9.60M | 7.76M | 5.70M | 5.74M | 7.29M | 12.51M | 9.04M | 19.80M | 10.60M | 2.60M |
| Interest Income | 0.00 | 54.61K | 16.36K | 6.71K | 1.54K | 7.45K | 9.30K | 1.29K | 3.84K | 5.06K | 115.00 | 34.00 | 35.00 | 587.00 | 3.15K | 9.02K | 0.00 | 87.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 54.61K | 16.36K | 18.08K | 0.00 | 0.00 | 0.00 | 1.29K | 0.00 | 2.67K | 70.80K | 178.97K | 131.84K | 95.14K | 154.03K | 116.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 150.77K | 144.38K | 128.93K | 130.28K | 256.47K | 881.29K | 573.15K | 163.37K | 97.38K | 95.84K | 96.12K | 95.13K | 105.39K | 128.64K | 126.39K | 127.24K | 148.91K | 118.76K | 118.15K | 101.92K | 335.22K | 417.99K | 435.18K | 718.62K | 732.86K | 500.00K | 300.00K | 200.00K |
| EBITDA | -6.96M | -8.68M | -7.30M | -7.36M | -3.90M | -5.58M | -4.66M | -6.35M | -2.96M | -694.34K | 1.18M | -596.20K | -1.24M | -572.20K | -2.10M | -1.73M | -3.24M | -3.52M | -3.13M | -2.91M | -1.40M | -1.25M | -2.77M | -6.12M | -5.45M | -10.50M | -7.20M | -2.10M |
| EBITDA Ratio | -70.78% | -98.61% | -70.89% | -135.31% | -1.28% | -41.97% | -41.32% | -60.59% | -31.18% | -15.48% | 2.68% | -6.89% | -11.83% | -7.72% | -22.50% | -33.97% | -53.23% | -63.09% | -62.63% | -61.17% | -35.17% | -32.04% | -69.12% | -103.48% | -162.54% | -123.86% | -262.07% | -766.67% |
| Operating Income | -7.11M | -8.83M | -7.38M | -7.45M | -4.00M | -8.00M | -5.23M | -6.51M | -3.06M | -790.18K | 1.09M | -520.35K | -1.22M | -700.84K | -2.10M | -1.73M | -3.24M | -3.52M | -3.25M | -3.01M | -1.73M | -1.67M | -3.20M | -6.84M | -6.18M | -11.00M | -7.70M | -2.30M |
| Operating Income Ratio | -72.31% | -100.24% | -71.60% | -137.08% | -47.75% | -83.14% | -46.40% | -62.14% | -32.20% | -7.65% | 10.85% | -6.02% | -14.60% | -7.19% | -24.61% | -26.10% | -50.70% | -60.28% | -50.47% | -63.31% | -43.61% | -40.98% | -78.18% | -120.48% | -216.49% | -125.00% | -265.52% | -766.67% |
| Total Other Income/Expenses | 125.53K | 54.61K | 259.82K | -18.08K | -3.64M | 215.00 | 4.37K | -3.80K | -1.51K | -907.81K | 378.23K | -349.95K | -258.50K | 86.33K | 573.43K | 541.13K | 301.55K | 370.52K | 492.87K | 11.34K | 0.00 | 53.93K | 64.49K | -246.28K | -807.60K | 400.00K | 0.00 | 200.00K |
| Income Before Tax | -6.98M | -8.77M | -7.12M | -7.47M | -7.64M | -8.00M | -5.23M | -6.52M | -3.06M | -1.70M | 1.46M | -870.31K | -1.35M | -519.96K | -2.16M | -1.08M | -2.94M | -3.15M | -2.27M | 0.00 | 0.00 | -1.62M | -3.14M | -7.08M | -6.99M | -10.60M | -7.50M | -2.10M |
| Income Before Tax Ratio | -71.04% | -99.62% | -69.08% | -137.41% | -91.27% | -83.13% | -46.36% | -62.18% | -32.22% | -16.43% | 14.63% | -10.06% | -16.12% | -5.33% | -25.23% | -16.31% | -45.98% | -53.94% | -35.26% | 0.00% | 0.00% | -39.66% | -76.60% | -124.82% | -244.77% | -120.45% | -258.62% | -700.00% |
| Income Tax Expense | 0.00 | -66.74K | 333.00 | 15.50K | 18.13K | 23.99K | 19.09K | -19.10K | 36.16K | 9.51K | -843.94K | 7.95K | 258.50K | -86.33K | -573.43K | -541.13K | -301.55K | -370.52K | -413.94K | -11.34K | 680.86K | 770.64K | 791.16K | 673.22K | 790.58K | -300.00K | -300.00K | -400.00K |
| Net Income | -6.93M | -8.71M | -7.12M | -7.49M | -7.66M | -7.43M | -5.19M | -5.95M | -5.47M | -1.70M | 1.46M | -870.31K | -1.48M | -614.51K | -1.53M | -1.19M | -2.94M | -3.15M | -2.75M | -3.00M | -2.41M | -2.44M | -3.99M | -7.51M | -6.97M | -10.70M | -7.40M | -1.90M |
| Net Income Ratio | -70.51% | -98.87% | -69.09% | -137.69% | -91.49% | -77.24% | -45.97% | -56.73% | -57.60% | -16.47% | 14.63% | -10.06% | -17.69% | -6.30% | -17.90% | -17.93% | -45.98% | -53.94% | -42.81% | -63.08% | -60.75% | -59.90% | -97.51% | -132.35% | -244.17% | -121.59% | -255.17% | -633.33% |
| EPS | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.09 | -0.05 | -0.10 | -0.04 | -0.11 | -0.09 | -0.24 | -0.27 | -0.25 | -0.33 | -0.52 | -0.59 | -1.07 | -2.15 | -2.40 | -3.66 | -3.63 | -1.29 |
| EPS Diluted | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.08 | -0.05 | -0.10 | -0.04 | -0.11 | -0.09 | -0.24 | -0.27 | -0.25 | -0.33 | -0.52 | -0.59 | -1.07 | -2.15 | -2.40 | -3.66 | -3.63 | -1.29 |
| Weighted Avg Shares Out | 72.78M | 70.61M | 68.83M | 63.06M | 45.74M | 35.30M | 32.70M | 26.97M | 21.03M | 20.06M | 17.13M | 16.08M | 15.17M | 14.82M | 13.39M | 12.67M | 12.14M | 11.79M | 11.01M | 9.15M | 4.67M | 4.16M | 3.71M | 3.50M | 2.91M | 2.92M | 2.04M | 1.47M |
| Weighted Avg Shares Out (Dil) | 72.78M | 70.61M | 68.83M | 63.06M | 45.74M | 35.30M | 32.70M | 26.97M | 21.43M | 20.06M | 17.48M | 16.08M | 15.17M | 14.82M | 13.39M | 12.67M | 12.14M | 11.79M | 11.01M | 9.15M | 4.67M | 4.16M | 3.71M | 3.50M | 2.91M | 2.92M | 2.04M | 1.47M |
Milestone Scientific Schedules Second Quarter 2024 Financial Results and Business Update Conference Call
ROSELAND, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time...
Milestone Scientific Announces Strategic Partnership with Axial Biologics to Distribute CompuFlo® in New Jersey, Texas, and Florida
ROSELAND, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced a strategic partnership with Axial Biologics, a premier medical device company...
Milestone Scientific Secures Key Patent Approvals in the U.S. and Europe
ROSELAND, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced receipt of multiple Notices of Allowance (NOA) for essential patent applications...
Milestone Scientific Announces Medicare Price Assignment for the CompuFlo® Epidural System in Texas, Pennsylvania, New Jersey, Maryland, Colorado, Oklahoma, Louisiana, Arkansas, Mississippi, New Mexico, District of Columbia, and Delaware
ROSELAND, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Novitas Solutions, Inc. (Novitas), a Jurisdictional Medicare Administrative Contractor (JMAC),...
Milestone Scientific Receives Regulatory Approval to Market CompuFlo® Epidural System in Brazil
Brazil is the 9th largest economy in the world with more than 21 million people suffering from chronic back pain
Milestone Scientific Inc. (MLSS) Q1 2024 Earnings Call Transcript
Milestone Scientific Inc. (MLSS) Q1 2024 Earnings Call Transcript
Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2024
Sales through new online portal increase 31% over the same period last year Gross margin for the first quarter of 2024 increases to 74.5% from 72.7% for the same period last year Reports steady progress on reimbursement strategy for the...
Milestone Scientific Schedules First Quarter 2024 Financial Results and Business Update Conference Call
ROSELAND, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time...
Milestone Scientific Inc. (MLSS) Q4 2023 Earnings Call Transcript
Milestone Scientific Inc. (MLSS) Q4 2023 Earnings Call Transcript
Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023
Reports acceleration of reimbursement claims submission for the CompuFlo® Epidural System Technology Reports acceleration of reimbursement claims submission for the CompuFlo® Epidural System Technology
Source: https://incomestatements.info
Category: Stock Reports